Evaluation of Toll-Like Receptors 2/3/4/9 Gene Polymorphisms in Cervical XXXX Evolution.

@entity1 @entity6800 @entity286 @entity5 @entity63990 @entity6801 @entity4022 @entity2938 @entity19825 @entity71042 @entity2939 @entity71043 @entity2574
UNASSIGNED: Accumulative epidemiological evidence suggests that polymorphisms of Toll-like receptors signaling pathway elucidated the cellular and molecular mechanisms of @entity1 diseases whose gaining a primordial importance. The aim of our study is to identify the role of @entity2938 ( @entity63990 ), @entity6800 ( @entity71042 ), @entity2939 ( @entity19825 ) and @entity6801 ( @entity71043 ) gene polymorphisms with the evolution of cervical @entity5 in Tunisian @entity1 . Blood samples were collected from histopathologically confirmed @entity1 with cervical @entity5 and unrelated healthy female controls of similar ethnicity. Genotyping of the analyzed polymorphisms were done using Polymerase Chain Reaction and Restriction Fragment Length Polymorphism. For the @entity2938 , Ins/Ins genotype is a protector factor [p  =  0.006; OR: 0.35(0.16-0.73)] and the dominant genotype of @entity6800 increased the risk of CC in stage (III+IV); C/C versuss C/T [p  =  0.033; OR: 2.03(1.00-4.13)] and C/C versus C/T+T/T [p  =  0.036; OR: 1.93(1.00-3.74)]. For @entity2939 , the dominant genotype @entity2574 / @entity2574 is implicated in the occurrence of CC in stage (I+II) [p  =  0.000; OR: 4.55(1.58-13.06)], [p  =  0.001; OR: 3.49(1.44-8.45)] and in stage (III+IV) [p  =  0.038; OR: 3.77(0.87-16.29)], [p  =  0.007; OR: 5.21(1.65-16.46)] and the major allele @entity2574 is a risk factor for the development of @entity5 in stage (I+II). The @entity2938 Ins/Del genotype is associated with @entity5 evolution to stage (III+IV) [p  =  0.003; OR: 3.00 (1.22-7.35)] and the genotypes @entity4022 / @entity4022 and @entity2574 / @entity4022 + @entity4022 / @entity4022 and @entity4022 allele of @entity2939 are implicated in @entity5 evolution to the advanced stages. Further, @entity2938 , @entity6800 , @entity2939 and @entity6801 gene polymorphisms are implicated in the modulation of CC risk due to @entity286 usage and statue of menopause among cases. Our study suggests a relationship between the incidence of the @entity2938 , @entity6800 , @entity2939 and @entity6801 mutations and the clinical progression of CC according to the FIGO classification. However, future studies with different demographic and clinical characteristics in ethnically diverse populations may provide a more comprehensive involvement of innate immunity in cervical @entity5 etiology in @entity1 worldwide.
